Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04276376
Title	Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors (ARIANES)
Acronym	ARIANES
Recruitment	Suspended
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	Gustave Roussy, Cancer Campus, Grand Paris
Indications	prostate cancer Advanced Solid Tumor gastroesophageal junction adenocarcinoma lung non-small cell carcinoma clear cell renal cell carcinoma bladder urothelial carcinoma gastric adenocarcinoma
Therapies	Atezolizumab + Rucaparib
Age Groups:	senior \| adult
Covered Countries	FRA